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Abstract
Background: In multiple myeloma (MM), increased neoangiogenesis contributes to tumor growth
and disease progression. Increased levels of endothelial progenitor cells (EPCs) contribute to
neoangiogenesis in MM, and, importantly, covary with disease activity and response to treatment.
In order to understand the mechanisms responsible for increased EPC levels and neoangiogenic
function in MM, we investigated whether these cells were clonal by determining X-chromosome
inactivation (XCI) patterns in female patients by a human androgen receptor assay (HUMARA). In
addition, EPCs and bone marrow cells were studied for the presence of clonotypic immunoglobulin
heavy-chain (IGH) gene rearrangement, which indicates clonality in B cells; thus, its presence in
EPCs would indicate a close genetic link between tumor cells in MM and endothelial cells that
provide tumor neovascularization.
Methods: A total of twenty-three consecutive patients who had not received chemotherapy were
studied. Screening in 18 patients found that 11 displayed allelic AR in peripheral blood mononuclear
cells, and these patients were further studied for XCI patterns in EPCs and hair root cells by
HUMARA. In 2 patients whose EPCs were clonal by HUMARA, and in an additional 5 new patients,
EPCs were studied for IGH gene rearrangement using PCR with family-specific primers for IGH
variable genes (VH).
Results: In 11 patients, analysis of EPCs by HUMARA revealed significant skewing (≥ 77%
expression of a single allele) in 64% (n = 7). In 4 of these patients, XCI skewing was extreme (≥
90% expression of a single allele). In contrast, XCI in hair root cells was random. Furthermore, PCR
amplification with VH primers resulted in amplification of the same product in EPCs and bone
marrow cells in 71% (n = 5) of 7 patients, while no IGH rearrangement was found in EPCs from
healthy controls. In addition, in patients with XCI skewing in EPCs, advanced age was associated
with poorer clinical status, unlike patients whose EPCs had random XCI.
Conclusion: Our results suggest that EPCs in at least a substantial subpopulation of MM patients
are related to the neoplastic clone and that this is an important mechanism for upregulation of
tumor neovascularization in MM.
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Increased neoangiogenesis has a governing role in the
pathogenesis and progression of multiple myeloma (MM)
[1], and is a reliable treatment target that has significantly
improved outcome [2-6]. Increased circulating endothe-
lial cells in cancer contribute to tumor neovascularization
and growth [7,8].
We recently showed that in MM, elevated levels of circu-
lating endothelial progenitor cells (EPCs) covary with dis-
ease activity, measured as serum M-protein and β2-
microglobulin levels, underscoring the role of EPCs in
MM pathogenesis [9]. Expression by EPCs of the early
hematopoietic markers CD34 and CD133 indicates that
these cells are derived from hematopoietic progenitor
cells in the bone marrow (BM) [9-12]. Experimental evi-
dence shows that in MM, EPCs both in circulation and in
the BM express angioblastic features–a high capacity for
vasculogenesis and a pro-angiogenic gene expression pat-
tern–suggesting that these cells resemble embryonic
angioblasts, and also supporting the thesis that BM EPCs
help tumor neovascularization [8,11,13]. These observa-
tions prompted us to explore whether EPCs in MM display
neoplastic features such as clonal restriction. Clonality in
EPCs from MM patients was determined by X-chromo-
some inactivation (XCI) patterns using a highly polymor-
phic CAG repeat in the androgen receptor (AR) gene, a
well-established method to assess clonality of tumor cells
[14] based on random epigenetic inactivation of one of
the two X chromosomes inherited from either parent [15].
Since the XCI pattern is stably inherited by all daughter
cells, polyclonal cell populations reflect mosaicism, while
in clonal neoplastic cells, the pattern is uniform [16]. We
found that EPCs displayed significantly skewed XCI pat-
terning (≥ 77% inactivation of one allele) in 64% of
patients, while the hair root cells showed random XCI.
Furthermore, there was evidence of immunoglobulin VH
gene rearrangement in EPCs in a manner characteristic of
clonal B lymphocytes, indicating that clonal EPCs are
related to neoplastic MM cells at the genetic level. Thus,
we suggest that myeloma-related genomic changes
include the endothelial genome and constitute the basis
for increased tumor neovascularization and growth.
Methods
Subjects
Twenty-three consecutive MM patients diagnosed by
Southwest Oncology Group criteria [17] were studied
according to protocols approved by the Institutional
Review Board of State University of New York Downstate
Medical Center, and informed consent was obtained in
accordance with the Declaration of Helsinki. Clinical
stage was determined according to Durie and Salmon
[18]; in addition to stage, serum β2-microglobulin and
albumin and, when feasible, tumor cell karyotype
(Wycoff Heights Medical Center, Brooklyn, NY) consti-
tuted clinical prognostic indicators [19] (Table 1). Fifteen
healthy hospital staff served as controls.
Table 1: Clinical characteristics of patients
Case 
Number
Age/Sex Source of 
EPC
%Plasma 
Cells in BM†
M protein 
(g/dL)
β2-microglob-
ulin (mg/L)
Albumin 
(mg/mL)
Durie/
Salmon 
Stage
Cytogeneti
cs‡
1 53/F PBMC 10 1.2, IgG κ 1.6 2.3 2A ND
2 62/F PBMC 30 1.2, IgG λ 1.8 3.5 2A Normal
3 60/F PBMC 40 2.4, IgG κ 2.2 4.0 2A ND
4 70/F PBMC 80 6.0 IgG κ 3.0 3.5 3A ND
5 54/F PBMC 15 1.1, IgG κ 6.8 2.4 2A ND
6 55/F BM 10 3.0, IgG κ 2.0 3.4 2A Normal
7 50/F PBMC 30 4.8, IgG κ 4.6 3.7 3A ND
8 46/F PBMC 10 2.8, κ LC 4.9 3.9 3A ND
9 52/F BM 5 1.1, IgG κ 2.6 4.0 1A ND
10 56/F PBMC 30 2.0, λ LC 1.4 4.2 3A ND
11 73/F BM 10 3.0, IgG κ 2.4 3.8 1A Normal
12 66/M BM 10 3.0, IgG κ 2.0 4.1 1A ND
13 56/F BM 95 7.0, IgG κ 3.7 3.2 3A Normal
14 54/F BM 90 2.9, IgG λ 1.8 4.0 2A ND
15 53/M BM 95 3.6, IgA κ 3.0 3.0 3A Normal
16 66/F BM 60 5.4, IgA λ 3.5 1.9 3A Normal
†Percent of plasma cells in BM indicates extent of myeloma involvement determined by histochemistry in the BM biopsies
‡Normal cytogenetics indicates results of chromosome banding studies and FISH performed using DNA probe D13S319 (Vysis Inc., Vysis, IL) for 
detection of 13q14.2 deletion
This patient had antecedent MGUS 
"PBMC" peripheral blood mononuclear cells; "BM" bone marrow; "ND" Not donePage 2 of 12
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Confluent EPCs were outgrown from peripheral blood
mononuclear cells (PBMCs) and from BM for DNA extrac-
tion. EPCs outgrown from PBMCs were preferentially
used; however, when DNA from EPCs derived from
PBMCs was not sufficient for the outlined studies, DNA
from EPCs grown from BM was used. The EPC DNA for
each patient was obtained from only one source, i.e.,
either from peripheral blood or from BM aspirate, as indi-
cated in Tables 1, 2, 3. To grow EPCs, heparinized periph-
eral blood (20 ml), or a single-cell suspension of bone
marrow (10 ml) was separated by Ficoll-Hypaque (Sigma
Chemicals, St. Louis, MO) density-gradient centrifugation
within 6 hours of collection. The mononuclear cell layer
was resuspended in EndoCult Basal Medium supple-
mented with 20% fetal bovine serum (StemCell Technol-
ogies, Vancouver, Canada) and antibiotics (100 U/ml
penicillin G, 100 μg/ml streptomycin). Ficoll-separated
mononuclear cells from peripheral blood or bone marrow
(7 × 106/well) were grown to confluence in laminin-
coated, 6-well plates (Becton Dickinson Labware, Bed-
ford, MA) as previously described [9,20]. Under these cul-
ture conditions, EPC colonies are observed at 14 to 18
days, and confluence is reached 18 to 28 days after plating
peripheral blood or bone marrow cells. To determine
endothelial cell phenotype and purity of outgrown cells,
EPCs were also grown on laminin-coated, 96-well plates
(Becton Dickinson Labware) and subjected to two-color
immunostaining with combinations of antibodies
directed against endothelial cell markers, including vascu-
lar endothelial growth factor receptor-2 (kinase insert
domain-containing receptor/fetal liver kinase-1 [KDR]),
CD133, CD144 (vascular endothelial cadherin [VE-cad-
herin]), and von Willebrand factor (vWF) as we previ-
ously described [9]. Anti-CD38-PE (BD PharMingen, San
Diego, CA) was employed to detect MM cells; TO-PRO-3
(Molecular Probes, Eugene, OR) was used to counterstain
the nuclei of EPCs (Figure 1). Appropriate isotype-
matched serum with each of the antibodies was used as
negative control. Images of the stained cells were digitally
recorded in the sequential mode on a confocal laser scan-
ning microscope (Bio-Rad MRC 1024ES, Bio-Rad, Her-
cules, CA). Percent positive cells were quantitated in a
minimum of 3 fields (original × 40) per well. In addition,
viable EPCs, after detachment from laminin (Cell Dissoci-
ation Buffer, Invitrogen, Carlsbad, CA), were stained
using direct immunofluorescence with indicated combi-
nations of anti-vWF-FITC (Serotec, Raleigh, NC), anti-
CD38-PE (BD PharMingen), anti-CD133-PE (Miltenyi
Biotec, Auburn, CA), and anti-CD45-PECy5 (eBioscience,
San Diego, CA), as well as isotype-specific control anti-
bodies, and analyzed with a FACSort flow cytometer (BD
Biosciences) as previously described [9]. To assure
absence of contaminating plasma cells, bone marrow
aspirates were also stained for the plasma cell marker
CD38 using anti-CD38-PE and analyzed by flow cytome-
try (see Additional file 1).
Human AR assay
Human androgen receptor gene assay (HUMARA) was
used to examine XCI status of EPCs and non-endothelial
cells to evaluate the clonal status of each population. Het-
erozygosity at the AR locus is a prerequisite for XCI evalu-
ation by HUMARA. Androgen receptor locus was
Table 2: X-chromosome inactivation patterns in EPCs and hair root cells from MM patients. XCI patterns were determined in DNA 
from EPCs and hair root cells from 11 MM patients who had polymorphic AR status. The methylation status of a highly polymorphic 
CAG repeat in the AR gene was determined using the methylation-sensitive restriction enzyme HpaII and PCR. Densitometric 
analyses of band intensities include normalization of the ratios, based upon the undigested samples. This was determined by dividing 
the allele ratio of the digested sample by the ratio of the undigested sample from the same specimen. This ratio corrects for 
preferential amplification of one allele, which often occurs for the shorter microsatellite allele. In EPCs from 6 patients whose EPCs 
and hair root cells were studied, the percent of skewing in XCI towards one inactivated allele was significantly greater in EPCs 
compared to hair root cells (*p = .03). "NA" indicates not available.
Case Number† EPC (Allele ratio) Hair root cell (Allele ratio) EPC Source
1 95:5 50:50 PBMC
2 97:3 55:45 PBMC
3 92:8 NA PBMC
4 90:10 NA PBMC
5 82:18 54:46 PBMC
6 77:23 51:49 BM
7 55:45 55:45 PBMC
8 54:46 56:44 PBMC
9 84:16 NA BM
10 51:49 Not done PBMC
11 52:48 Not done BM
Mean: *75:25 53.5:46.5
†Case number refers to cases detailed in Table 1Page 3 of 12
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polymerase chain reaction (PCR) assay in DNA extracted
from PBMCs, as described previously [21]. Definitive pol-
ymorphism in the human AR locus was found in 11 of the
18 patients studied (Table 1, Cases 1–11). In the remain-
ing 7 patients, the AR locus did not display obvious heter-
ozygosity (data not shown) and therefore these patients
were not candidates for evaluation of EPC clonality using
HUMARA. Within a monoclonal cell population in a
woman, all cells have the same combination of active and
inactive X chromosomes. The maternally and paternally
inherited X chromosomes can be distinguished by poly-
morphisms involving the number of tandemly repeated
CAG repeats within the AR gene. Using AR-specific PCR
primers that flank the CAG repeats, two PCR products of
different sizes can be amplified from a heterozygous
patient's genomic DNA. The primers that flank the AR
CAG repeat sequence also span an HpaII restriction site
(CCGG) that is methylated and thereby protected from
digestion when present on an inactive X chromosome, but
is unmethylated and thereby susceptible to digestion
when present on an active X chromosome. Thus, when
HpaII-treated DNA is subjected to PCR with AR-specific
primers, copies of the inactive allele are amplified,
whereas copies of the active allele are cleaved by HpaII and
cannot yield a PCR product. As a result, a single product is
obtained after amplification of DNA from a clonal cell
population from a heterozygous female patient. DNA was
extracted from confluent EPCs, intact hair roots, and
PBMCs using the QIAamp DNA Mini Kit (QIAGEN,
Valencia, CA). DNA samples were divided into two iden-
tical aliquots, one of which was incubated overnight at
37°C with the methylation-sensitive restriction enzyme
HpaII for the digestion of unmethylated (or active) alleles.
A second restriction enzyme, RsaI, which recognizes a
four-base pair sequence not present in the amplified
region of the AR locus, was also included in the reaction
to facilitate the HpaII digestion process. Male DNA with
cytogenetically verified 46XY karyotype was used as con-
trol for complete digestion.
Both digested and undigested DNA samples were ampli-
fied using AR-specific primers 5'-GTC CAA GAC CTA CCG
AGG AG-3' and 5'-CCA GGA CCA GGT AGC CTG TG-3'.
Amplicons were labeled by including a radioactive nucle-
otide (α-[33P]-dCTP) (NEN, PerkinElmer Life Sciences,
Boston, MA) in the PCR. PCR products were separated on
8% denaturing gels, followed by autoradiography. Densi-
tometric analyses of the alleles, performed at least twice
for each sample using MultiAnalyst version 1.1 software
(Bio-Rad), included normalization of the ratios based
upon the non-digested samples by dividing the allele ratio
of the digested sample by the ratio of the non-digested
sample from the same specimen.
IGH gene rearrangement
One-step PCR as described by Deane and Norton [22] was
used to determine VH gene rearrangement within conflu-
ent EPCs and MM-cell-infiltrated BM aspirate samples. In
each experiment, genomic DNA extracted from unsepa-
rated BM aspirate containing 10%-95% MM cells (Table
3) was used to identify the clonotypic IG VH gene rear-
rangement within the neoplastic plasma cells. VH genes
were amplified from genomic DNA extracted from freshly
obtained bone marrow samples and primary EPCs using a
genomic DNA purification kit (Gentra Systems, Minneap-
olis, MN). A set of 7 VH family-specific PCR primers was
used to isolate the clonally expressed VHDHJH, as
described previously [22]. The forward primers were from
the first framework region of the most common VH family
members, and the single reverse JH primer was common to
the 3' end of all six JH genes. PCR products were run on a
1.0% agarose gel, where the VH gene rearrangement was
identified as a single band of 350 bp. For cloning and
sequencing, DNA was extracted from the resolved 350-bp
bands using the QIAquick Gel Extraction Kit (QIAGEN).
Dideoxy sequencing (GENEWIZ, North Brunswick, NJ)
Table 3: IG VH gene rearrangement in EPCs and BM cells in MM. A single 350-bp band was amplified using the indicated VH primers in 
BM cells and confluent EPCs from each patient.
Case Number EPC (VH primer) BM Cell (VH primer) % Plasma cells in BM EPC Source
1 VH4A VH4A 10 BM
2 VH4A VH4A 30 BM
12 VH5 VH5 10 BM
13 VH4A VH4A 95 BM
14 VH4A VH4A 90 BM
15 No rearrangement VH3 95 BM
16 No rearrangement VH3 60 BM
Controls
HUVECs No rearrangement --- --- ---
Healthy subject No rearrangement --- --- ---Page 4 of 12
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Figure 1
Characterization of confluent EPC cultures expanded from BM expressing KDR, VE-cadherin, CD133, and vWF. (A) Colony-forming and 
outgrowing endothelial cells from a representative patient are shown. A colony-forming unit expressing: (1) KDR (red), (2) VE-cadherin (green), and (3) 
merge shows independent cellular distribution of KDR and VE-cadherin. Outgrowing EPCs expressing: (4) KDR (green), (5) early hematopoietic antigen 
CD133 (red), and (6) merge show independent cellular localization of KDR and CD133. Cultures were maintained on 96-well, laminin-coated plates, 
where colony growth and confluent EPCs were observed after 14 and 18 days of culture, respectively. Indirect immunofluorescence was done with indi-
cated antibodies, and appropriate isotype-matched serum with each of the primary antibodies was used as negative control (not shown). Images of the 
stained cells were digitally recorded on a confocal laser scanning microscope (Bio-Rad MRC 1024ES; Bio-Rad, Hercules, CA) and were generated at the 
projections of the z-stacks at 1024 × 1024 pixels. (B) Co-staining of EPCs grown from BM for expression of vWF (green), CD38 (red), and nuclear coun-
terstain TO-PRO-3 (blue). Data from a representative patient show that EPCs are vWF-positive. Boxes on the left indicate patterns of immunocytochem-
ical staining of the same EPCs; 3-D histogram on the right shows 2-color FACS analysis using anti-vWF-FITC, anti-CD38-PE, and isotype-specific control 
antibodies. (C) Two-color dot plot of primary EPC culture from a representative patient using anti-vWF-FITC, anti-CD133-PE, and anti-CD45-PE/Cy5 
antibodies. Quadrants were set based upon isotype-specific controls for FITC and PE (and PE/Cy5, not shown). Numbers shown in the quadrants reflect 
percent of EPCs from which small, agranular debris was gated out based on forward and side scatter plots.
BMC Cancer 2006, 6:161 http://www.biomedcentral.com/1471-2407/6/161was performed using the same VH primer that was added
to the original PCR reaction. Nucleotide sequences of
amplified DNA were identified by BLAST and compared
by FASTA.
To rule out false-positive results due to contaminating
plasma cells, the sensitivity of the PCR system to detect
IGH rearrangement in EPCs was evaluated by quantitating
the minimum contamination with tumor DNA required
for IGH gene rearrangement. Thus, DNA samples from
human umbilical vein endothelial cells (HUVECs), which
do not have IGH rearrangement, were spiked with
decreasing percentages of DNA obtained from the MM
cell line U266, which has a clonotypic IGH rearrange-
ment. In these experimental conditions, 2% or more of
contaminating plasma cells were necessary to give positive
results for IGH gene rearrangement (data not shown). As
flow cytometry showed positivity of 0.1 ± 0.01% (n = 3)
in EPCs for the myeloma cell antigen CD38, IGH rear-
rangement observed in these cultures was concluded to be
a tumor-specific feature of EPCs. In addition to DNA
extracted from HUVECs, DNA from EPCs outgrown from
a healthy control were studied for VH rearrangement as
negative controls for these experiments.
Quantitation of rearranged IGH locus in primary EPCs by 
real-time PCR
To further rule out that plasma cell contamination in
EPCs could be responsible for IGH rearrangement found
in primary cultures, quantitation of EPCs containing the
IGH rearrangement was performed using SYBR Green I
real-time PCR. In B cell malignancies, quantitative real-
time PCR assays have been established that use tumor-
specific IGH rearrangements as quantitative markers of
tumor cells [23]. The amount of fluorescence produced by
this real-time PCR reaction is proportional to the starting
DNA target number during the early phases of amplifica-
tion. DNA from primary EPCs from Case 15, which con-
tained the clonotypic rearrangement found in BM cells,
was PCR-amplified using VH4A forward and JH reverse
primers [22], and cloned using a TA Cloning Kit (Invitro-
gen, Carlsbad, CA) following recommended procedures.
Briefly, about 5 ng of fresh PCR product was ligated to 50
ng of pCR2.1 at equal molar concentrations overnight at
16°C. Competent DH5α Escherichia coli were transformed
with 20% of the ligation reaction and plated on LB agar
with 100 μg/mL of ampicillin. Recombinant plasmid con-
taining the ligated PCR-amplified IGH gene product was
recovered with a QIAGEN Miniprep DNA purification sys-
tem (QIAGEN) and digested with EcoRI to confirm pres-
ence of insert. Sequencing of cloned plasmid DNA using
the M13 reverse primer (GENEWIZ) also confirmed the
inserted patient-specific IGH rearrangement (data not
shown).
Plasmid DNA containing human apolipoprotein B100
(ApoB) [24] was obtained from Kezhi Dai for use as an
internal standard to normalize genomic DNA levels of
IGH rearrangement in EPCs and BM cells from the same
patient, as described for detection of minimal residual dis-
ease in acute lymphoblastic leukemia [25,26]. Quantita-
tive PCR was performed using the qPCR Core Kit for SYBR
Green I (Eurogenetec, San Diego, CA). Reactions per-
formed in duplicate for IGH quantitation contained 10 ng
of either EPC or BM cell genomic DNA from Case 15, and
2 × qPCR master mix containing 8 μM of either IGH prim-
ers (VH4 forward 5'-TCGGAGACCCTGTCCCTCACCT-
GCA-3', patient allele-specific reverse 5'-
CCAGAGATCGAAGAACCAGTCTTC-3') or ApoB primers
(ApoB forward 5'-GCAAG CAGAA GCCAG AAGTG A-3',
ApoB reverse 5'-CCATT TGGAG AAGCAGTTTG G -3').
Amplification conditions, using an ABI Prism 7000
sequence detector equipped with a 96-well thermal cycler
(Applied Biosystems, Foster City, CA), were 10 minutes at
95°C (to activate the enzyme) and 40 cyclesof denatura-
tion at 95°C for 15 seconds and annealing/extension at
60°C for 1 minute. Data were collected and analyzed with
ABI Prism SDS software v1.0 (Applied Biosystems, Foster
City, CA). To obtain a standard curve for quantifying
patient BM and EPC DNA, IGH and ApoB plasmids were
diluted in 4-fold increments and subjected to quantitative
PCR in duplicate as previously described [25]. Standard
curves plotting cycle threshold (CT) versus log number of
copies were produced with correlation coefficients greater
than or equal to 0.97. Copy numbers of ApoB and rear-
ranged IGH loci in EPCs and BM were obtained from
these standard curves. Percent of cells bearing the IGH
rearrangement was calculated as 100% × (log copy num-
bers of IGH/log copy numbers of ApoB).
Statistical analysis
Data are presented as means ± standard deviations. Stu-
dent's t test, two-tailed, was used to compare indicated
groups. Associations between variables were evaluated by
Pearson's r. Significance was set at p ≤ .05.
Results and discussion
Confluent primary EPCs outgrown from patients' PBMCs
or BM were the source of genomic DNA used in our exper-
iments. Phenotypic characterization of PBMC- or BM-
derived EPCs by immunocytochemistry and flow cytome-
try showed that at Days 14–18 of culture, EPCs expressed
KDR, VE-cadherin, and CD133 antigens (Figure 1A). Spe-
cifically, flow cytometric analysis showed that 94 ± 2.5%
(n = 4) of EPCs expressed the endothelial antigen vWF,
while less than 0.3 ± 0.01% (n = 3) of EPCs expressed the
neoplastic plasma cell marker CD38. A significant major-
ity of vWF-positive EPCs expressed the early endothelial
antigen CD133 and were null for the leukocyte-common
antigen, CD45 (Figure 1 A–C). Persistence of CD133Page 6 of 12
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during EPC maturation, and studies are underway in our
laboratory to further assess expression of CD133 at the
mRNA and protein levels in MM EPCs.
These data indicate that, irrespective of the source, i.e.,
PBMCs or BM, the EPC culture conditions, which lack
exogenously added growth factors or cytokines (other
than fetal bovine serum), and from which nonadherent
cells are removed every three days, do not allow propaga-
tion of MM cells, which are known to be non-adherent, or
other hematopoietic cells. In fact, the overwhelming vWF
positivity observed at Days 14–18 indicated that cell types
other than EPCs were not expanded in this culture system,
indicating that culturing cells on laminin (and not meth-
ylcellulose), and in the absence of exogenously added fac-
tors, probably contributed to the absence of
hematopoietic or stromal cell growth.
To determine clonality within EPCs, we studied XCI pat-
terns of these cells and compared them to XCI patterns of
non-endothelial cells (hair root from the same patient)
using HUMARA. Polymorphism in the human AR locus
was found in 11 female patients, who were thus candi-
dates for this analysis. As shown in Figure 2A, undigested
DNA from EPCs or hair root cells yielded two alleles in a
MM patient heterozygous for the analyzed polymor-
phism. In EPCs, digestion with the methylation-sensitive
enzyme HpaII targeted the unmethylated AR allele in all of
the cells, resulting in a skewed XCI pattern, indicated by a
single band, while in hair root cells, random XCI caused
targeting and amplification of both AR alleles, as indi-
cated by the two bands. Determination of XCI patterns in
candidate patients showed that 7 of the 11 patients had
skewing in XCI, indicated by a 77% or greater inactivation
of one allele (Table 2). Of the 7 patients whose XCI pat-
terns displayed skewing, 4 displayed extreme skewing (≥
90% inactivation of one allele). Extremely skewed XCI is
a rare event, reported in only 2–4% of 55–72-year-old
women [27], and age was found not to contribute to
skewing of XCI profiles in our patients (data not shown).
It was important to establish that the X-inactivation pro-
file of the EPCs in the study was not skewed due to a pri-
mary cause, which would be represented in the majority if
not all of the tissues. Therefore, hair root, an ectoderm-
derived tissue, was used in addition to mesodermal EPCs
to examine XCI patterns. The difference in XCI patterns
between EPCs and hair root cells in 6 patients (p = .03;
Table 2) argues against a tissue-specific XCI distribution,
as well as against primary causes for skewing, which
would affect all cells [28]. Chemotherapy may cause sec-
ondary skewing in XCI; however, none of the patients
were receiving chemotherapy. Preferential expansion of a
single normal clone of EPCs is unlikely to be responsible
for the skewing observed in XCI profiles, because DNA in
each case was derived from numerous EPC-colony-form-
ing units that expanded within the same time frame to
contribute to the final confluent EPC population studied.
To control for the skewing in XCI patterns observed in
2–5% of women in normal populations, we also com-
pared patterns from patient EPCs to those from control
PBMCs (Figure 2B), and found that mean skewing in XCI
was significantly greater in patients compared to controls
(p = .05), suggesting that the XCI pattern observed in MM
patients' EPCs is unlikely to be part of a normal pattern.
In the latter study, we ideally wanted to compare XCI pat-
terns in EPCs between patients and controls. However, in
the absence of exogenously added cytokines or growth
factors, we were only able to obtain confluent EPCs in 1
of 7 healthy control patients. We therefore used PBMCs
from normal controls to determine their XCI patterns.
To further explore genomic characteristics of MM EPCs,
we determined VH gene rearrangement in tumor-contain-
ing BM cells and in confluent EPCs. Cells committed to
the B cell lineage rearrange IG heavy- and light-chain
genes at the DNA and mRNA levels, while non-B cells
retain their genomic (non-rearranged) state. In MM, as in
other late B cell malignancies, rearrangements in the IG
heavy- and light-chain genes have been used to detect
monoclonality [29,30]. We studied EPCs for evidence of
IGH gene rearrangement by determining the VHDJH
region rearrangement. This approach was chosen because
it allowed us to determine clonality in cells from both
male and female patients; this approach also provided
information about the clonal similarity between EPCs and
neoplastic plasma cells, since all of the cells belonging to
a clone would have the identical clonotypic VH region
rearrangement.
To study VH gene rearrangement in EPCs, we used a previ-
ously described panel of VH primers in conjunction with a
single JH primer common to the 3' end of all six JH genes
[22]. Each primer was specific to the first framework
region of the most common VH family members [31]. As
shown in Figure 3A, in which are presented results from a
representative patient (Case 1), we found a single 350-bp
VH4 product in EPCs, indicating that these cells had rear-
ranged their IGH gene. In addition, BM plasma cells from
the same patient also showed VH gene rearrangement,
indicated by a similar 350-bp VH4 product. As summa-
rized in Table 3, 5 of 7 patients (71%) showed the same
single product after PCR amplification of EPC DNA as
well as unseparated BM DNA, suggesting the presence of
the same rearrangement in the VH gene both in EPCs and
in BM cells. Two of these 5 patients also had extremely
skewed XCI (Case 1), while the remaining 3 were not can-
didates for XCI analysis. The strong genetic linkage
between EPCs and MM cells indicated by rearrangement
of the VH gene in both cell types is strengthened by thePage 7 of 12
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and absence of VH mutations in EPCs and bone marrow
cells (IMGT, the International ImMunoGeneTics informa-
tion system, http://imgt.cines.fr). Furthermore, data from
the same patient also showed that 51% of the patient's
EPCs and 82% of the patient's BM cells contained the IGH
rearrangement. This was accomplished using SYBR Green
I quantitative real-time PCR, whereby copy numbers of
IGH rearrangement were compared to those of apolipo-
protein B100 (chromosome locus 2p24), which does not
undergo rearrangement (see Additional file 2). This result
is inconsistent with tumor contamination accounting for
IGH rearrangement by PCR, since flow cytometric analysis
did not show detectable numbers of plasma cells in EPC
cultures. The results are also in accord with recently pub-
lished data derived from 5 patients wherein an average of
18% of EPCs in MM patients were shown by fluorescent
in situ hybridization to have the MM-specific chromo-
somal translocations [32].
In EPCs from 2 patients and 1 healthy control, there was
no evidence of VH gene rearrangement. In addition,
HUVECs also did not have VH gene rearrangement (Table
3). Thus, VH gene rearrangement in EPCs is not universal
in MM, as supported by our finding of mosaic XCI pat-
terns in 4 patients (36%) (Table 2). These findings are not
unexpected, given the known genetic heterogeneity of
MM [29]. Limitations of the primers in detecting rear-
rangements involving other VH gene regions, biallelic rear-
rangements that reduce the intensity of clonal
amplifications, loss of primer annealing, or aberrant VH
gene rearrangements within the myeloma clone may also
have contributed to the lack of rearrangement in two
patients [30,33]. At present, events downstream from VH
gene rearrangement in EPCs, including IG transcription
and translation, are being studied.
Our results are in agreement with previous publications in
which a population of endothelial cells in chronic mye-
loid leukemia was shown to harbor the BCR/ABL fusion
gene [34], and, more recently, identical non-random
chromosomal translocations were found in endothelial
cells and neoplastic B cells in non-Hodgkin's lymphoma
[35], suggesting a genetic connection between these cells.
Of the patients tested, karyotype analysis by G-banding
did not reveal abnormalities that could be utilized to
compare EPCs to MM cells (Table 1).
Taken together, these results show for the first time that in
MM patients, EPCs, as distinct from non-hematopoietic
cells, display skewing in XCI. Furthermore, EPCs have VH
gene rearrangement identical to that found in neoplastic
plasma cells, suggesting that there may be clonal identity
between the two cell types. Genomic abnormalities in
EPCs are a critical aspect of the increased angiogenesis
associated with MM and the consequent detrimental
effect on disease progression, and thus require further
investigation.
Interesting clinical correlates of clonality were also
present. In patients whose XCI studies showed skewing (n
= 7), age was positively correlated with higher M protein
levels (r = .80, p = .03), greater BM plasma cell infiltration
(r = .97, p < .001), and more advanced stage of MM (r =
.81, p = .03). In contrast, in patients in whom EPCs had
random XCI (n = 4), these variables were unrelated or
inversely related to age. The effect was particularly evident
in the correlation of age with clinical stage (r = -.94, p =
X-chromosome inactivation patterns in EPCs from MM patientsFigu e 2
X-chromosome inactivation patterns in EPCs from MM patients. 
(A) X-chromosome inactivation status in a MM patient (Case 5, Table 1). 
XCI patterns were determined at least twice for each sample by incorpo-
rating α-[33P]-dCTP into the PCR reaction. For each sample, DNA was 
either undigested (-) or digested (+) with the methylation-sensitive restric-
tion enzyme HpaII. The PCR products were separated on 8% sequencing 
gels and subjected to autoradiography. Intensity of the specific bands cor-
responding to the AR gene demonstrates a skewed pattern of XCI (pre-
dominance of a single band) in EPCs, and a random pattern of XCI 
(presence of two bands of similar intensity) in hair root cells. A clonal pop-
ulation was defined as a cell population with greater than 77% expression 
of either one of the X-linked alleles. (B) Distribution of XCI patterns in 
MM patients and healthy controls. XCI patterns were determined in DNA 
from EPCs in MM patients (filled triangles), and PBMCs in healthy controls 
(open triangles) (*p = .05). For clarity, the y-axis begins at 40%.Page 8 of 12
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Figure 3
PCR analysis and sequencing of immunoglobulin VH gene rearrangement in EPCs in MM patients. A series of 7 VH family-specific primers 
(VH1–6) common to the most described members of the corresponding VH family, including two separate primers specific for the VH4 family (VH4A and -
4B), were used as forward primers. A consensus JH primer was used as reverse primer to amplify rearranged DNA, producing an expected 350-bp PCR 
product as described by Deane and Norton [22]. (A) Agarose gel analysis of VH4A family-specific IGH gene rearrangement detected in EPCs and BM cells 
from a MM patient. Briefly, 1 μg of genomic DNA was amplified with each of the VH family primers and the constant JH primer, which were added at a con-
centration of 1 μM each. Products were run on 1% agarose gels and visualized with ethidium bromide staining. DNA from MM cell line U266, which con-
tains a VH1-JH rearrangement, was amplified simultaneously as a positive control for rearrangement, shown as a 350-bp PCR product. Primers specific for 
apolipoprotein B served as a control to monitor the efficacy of PCR. M indicates marker (1 Kb Plus DNA Ladder [Invitrogen, Carlsbad, CA]). No products 
were detected from this patient's DNA with the VH5 or VH6 primers (not shown). (B) Sequence analysis of IGH rearrangement found in EPCs and BM 
cells from a MM patient. Sequences obtained from PCR amplification of IGH DNA in EPCs and BM cells shown from Case 14 were compared using 
FASTA. The 5' VH4A and JH regions identified by BLAST are shown above the sequences along with numbers indicating the length of the sequences ana-
lyzed. The VH4A-JH rearrangement in EPCs and BM cells from this patient has a 100% sequence overlap.
BMC Cancer 2006, 6:161 http://www.biomedcentral.com/1471-2407/6/161.06 for patients without skewing). Furthermore, as may be
seen in Tables 1 and 2, a greater proportion of patients
with EPCs that displayed random XCI had Stage 3 disease,
compared to patients with XCI skewing in EPCs (3/4 vs. 1/
7; P = .045, Fisher's Exact Test mid-P, two-tailed). The sig-
nificance of these data is as yet unknown, especially since
mean values of demographic and clinical characteristics
did not differ between patients with and without XCI
skewing in EPCs. However, these findings provide further
evidence that the pathogenesis and clinical course of MM
is differentially regulated based on genetic status of
involved cell types. In this regard, it is perhaps relevant
that constitutional XCI skewing is thought to mediate a
susceptibility to breast cancer and ovarian cancer, and is
hypothesized to be secondary to a skewed inactivation of
an X-linked tumor suppressor gene, or perhaps to a low-
penetrance susceptibility allele that is affected by the XCI
patterns [36].
In our studies, hair root control DNA for XCI studies was
not available for analysis in 3 patients who had skewed
XCI in EPCs (Cases 3, 4, and 9, Table 2); thus, these
patients were not included in the comparison of clonality
between hair root and EPCs discussed for Table 2. We are
planning to evaluate additional MM patients for constitu-
tional XCI skewing and its possible role in predisposing
patients to MM. This is especially relevant for our investi-
gations of MM because we find this disorder to be preva-
lent in women in our inner-city patient population [37].
Prospective studies are now in progress examining clonal-
ity and severity of MM; these will further elucidate the role
of EPC clonality in the natural history of this disease.
Conclusion
These results underscore the necessity to explore the the-
ses that MM cells and EPCs are derived from a multipotent
progenitor [38] or a MM stem cell capable of self-renewal
and differentiation [39], or are altered by factors that
cause identical changes in MM cells and EPCs. Studies that
examine the differentiation potential of single EPCs
obtained from MM patients, and that compare EPCs to
neoplastic plasma cells at the genetic level, are underway.
Answering these questions will enhance our current
understanding of MM angiogenesis and its relevance to
the treatment of MM [40-42].
While this manuscript was being revised, Rigolin et al.
[32] published data from 5 MM patients showing identi-
cal 13q14 deletion in circulating endothelial and bone
marrow plasma cells.
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